LONDON ¿ Cambridge Antibody Technology Group, of Royston, Cambridgeshire, is issuing a further 1.6 million CAT shares to Aptein Inc. shareholders to complete the acquisition of Aptein agreed to in July 1998.

The agreed price was US$11 million, of which $6 million was paid in CAT shares at the time of the deal. The new share issue for the balance follows the granting to Aptein of European patents for its polysome display technology. ¿ Nuala Moran